Genoptix, Inc. Announces Availability of MPL W515 L/K Mutation Analysis for
MPD at 49th Annual American Society of Hematology (ASH) Meeting
SAN DIEGO, Dec. 7 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX),
a provider of personalized diagnostic services, announced today at the ASH
Meeting in Atlanta, Georgia, that it will launch testing for the MPL W515 L/K
mutation. This new test further expands the Genoptix service offering for
patients with hematomalignancies, or cancers of the blood, to improve
diagnosis and management. Genoptix believes it will be the first commercial
hematology/oncology laboratory service provider to offer this test.
"Our ability to bring cutting-edge technologies to our physician partners,
like both quantitative JAK2 and MPL testing, furthers our commitment to
shepherding academic medicine to community-based practices," noted Tina Nova,
Ph.D., President and CEO of Genoptix. Mike Nerenberg, M.D., Vice President of
Business Development for Genoptix said, "MPL mutation analysis provides the
hematologist/oncologist with a new diagnostic tool in the identification and
management of myeloproliferative disorders, or MPD, a disease group that is
becoming better understood with the availability of molecular assays such as
this one."
MPL mutations, which affect the thrombopoietin receptor and result in the
continuous activation of Janus 2 kinase (JAK2) and other pathways, are
commonly associated with two myeloproliferative disorders, namely idiopathic
myelofibrosis (IMF) and essential thrombocythemia (ET). MPL W515 L/K mutation
analysis may be particularly useful for patients with suspected MPD that are
negative for JAK2 mutations.
Genoptix utilizes Invader Plus(R) technology to achieve specific and
sensitive detection of the MPL mutation.
About Genoptix, Inc.
Genoptix is a specialized laboratory service provider focused on
delivering personalized and comprehensive diagnostic services to
community-based hematologists and oncologists. Genoptix is headquartered in
Carlsbad, California.
Forward-Looking Statements.
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements include, but are not
limited to, statements related to the launch and effectiveness of new tests,
such as MPL W515 L/K mutation analysis, the utility of these tests as
diagnostic tools, and the ability of Genoptix to bring new technologies and
further expand its diagnostic services to its customers. Forward-looking
statements are not guarantees of performance. They involve known and unknown
risks, uncertainties and assumptions that may cause actual results, levels of
activity, performance or achievements to differ materially from those
expressed or implied by any forward-looking statement. These risks and
uncertainties include risks that may affect Genoptix business operations,
including changes in reimbursement levels, changes in regulations, payor
policies or contracting arrangements with payors, increased competition, the
limited operating history of Genoptix, dependence on Cartesian Medical Group
for the provision of medical services, difficulties in managing its growth,
and numerous regulatory and compliance risks, including compliance with
governmental payor regulations and compliance with rules and regulations in
California and other states. For information about risks and uncertainties
that Genoptix faces, please refer to the risk factors section of the final
prospectus from the Genoptix initial public offering filed with the United
States Securities and Exchange Commission on October 30, 2007, as well as
other subsequent filings with the Securities and Exchange Commission.
Genoptix assumes no obligation and expressly disclaims any duty to update any
forward-looking statement to reflect events or circumstances after the date of
this press release or to reflect the occurrence of unanticipated events. This
caution is made under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. All forward-looking statements are qualified in
their entirety by this cautionary statement.
Invader Plus(R) is a registered mark of Third Wave Technologies, Inc.
SOURCE Genoptix, Inc.
Marcy Graham, Sr. Director, Investor Relations of Genoptix, Inc.,
+1-760-930-7150, investorrelations@genoptix.com; or Joleen Schultz of Mentus,
+1-858-455-5500, ext. 215, jschultz@mentus.com, for Genoptix, Inc.
